In this context, a study described by Lerwill [57] looks at the discovery of MED12 mutations in the pathogenesis of fibroepithelial tumors, along with other gene abnormalities in the progression pathway, which has allowed for the improvement of prognosis and diagnosis. The gene discussed is MED12; the disease is fibroepithelial neoplasm.